Riggs M W, McNeil M R, Perryman L E, Stone A L, Scherman M S, O'Connor R M
Department of Veterinary Science and Microbiology, University of Arizona, Tucson, Arizona 85721, USA.
Infect Immun. 1999 Mar;67(3):1317-22. doi: 10.1128/IAI.67.3.1317-1322.1999.
The protozoan parasite Cryptosporidium parvum is an important cause of diarrhea in humans, calves, and other mammals worldwide. No approved vaccines or parasite-specific drugs are currently available for the control of cryptosporidiosis. To effectively immunize against C. parvum, identification and characterization of protective antigens are required. We previously identified CPS-500, a conserved, neutralization-sensitive antigen of C. parvum sporozoites and merozoites defined by monoclonal antibody 18.44. In the present study, the biochemical characteristics and subcellular location of CPS-500 were determined. CPS-500 was chloroform extractable and eluted with acetone and methanol in silicic acid chromatography, consistent with being a polar glycolipid. Following chloroform extraction and silicic acid chromatography, CPS-500 was isolated by high-pressure liquid chromatography for glycosyl analysis, which indicated the presence of mannose and inositol. To identify which component of CPS-500 comprised the neutralization-sensitive epitope recognized by 18.44, the ability of the monoclonal antibody to bind CPS-500 treated with proteases, or with alpha- or beta-glycosidases, was determined. Monoclonal antibody 18.44 did not bind antigen treated with beta-D-mannosidase but did bind antigen treated with alpha-D-mannosidase, other alpha- or beta-glycosidases, or a panel of proteases. These data indicated that the target epitope was dependent on terminal beta-D-mannopyranosyl residues. By immunoelectron microscopy, 18.44 binding was localized to the pellicle and an intracytoplasmic tubulovesicular network in sporozoites. Monoclonal antibody 18.44 also bound to antigen deposited and released onto substrate over the course travelled by gliding sporozoites and merozoites. Surface localization, adhesion and release during locomotion, and neutralization sensitivity suggest that CPS-500 may be involved in motility and invasion processes of the infective zoite stages.
原生动物寄生虫微小隐孢子虫是全球人类、犊牛和其他哺乳动物腹泻的重要病因。目前尚无批准用于控制隐孢子虫病的疫苗或寄生虫特异性药物。为了有效免疫微小隐孢子虫,需要鉴定和表征保护性抗原。我们之前鉴定了CPS-500,它是微小隐孢子虫子孢子和裂殖子的一种保守、对中和敏感的抗原,由单克隆抗体18.44定义。在本研究中,确定了CPS-500的生化特性和亚细胞定位。CPS-500可被氯仿提取,并在硅酸色谱中用丙酮和甲醇洗脱,这与它是一种极性糖脂一致。经过氯仿提取和硅酸色谱后,通过高压液相色谱分离CPS-500用于糖基分析,结果表明存在甘露糖和肌醇。为了确定CPS-500的哪个成分包含被18.44识别的对中和敏感的表位,测定了单克隆抗体与经蛋白酶、α-或β-糖苷酶处理的CPS-500结合的能力。单克隆抗体18.44不与经β-D-甘露糖苷酶处理的抗原结合,但与经α-D-甘露糖苷酶、其他α-或β-糖苷酶或一组蛋白酶处理的抗原结合。这些数据表明,靶表位依赖于末端β-D-甘露吡喃糖基残基。通过免疫电子显微镜观察,18.44的结合定位于子孢子的表膜和胞质内的微管泡网络。单克隆抗体18.44也与滑行子孢子和裂殖子移动过程中沉积并释放到底物上的抗原结合。表面定位、运动过程中的黏附和释放以及中和敏感性表明,CPS-500可能参与感染性滋养体阶段的运动和入侵过程。